Healthcare / BiotechnologyNasdaqGS
$8.64
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-92.7M · quality 61.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$195M
P/E
N/A
•EV/EBITDA
N/A
•ROE
66.9%
↑Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-51.6%
FCF / Net income
0.38x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $146.1M · net income $-196.0M · FCF $-75.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $146.1M | $146.1M | $145.2M | $146.0M | $157.1M | $209.8M | $108.1M | $40.9M | $30.3M | $1.6M | $154000.00 | $250000.00 | $229000.00 | $387000.00 | $634000.00 | $152000.00 | — | — |
| Net Income | $-196.0M | $-196.0M | $-76.4M | $-143.1M | $-165.3M | $-124.1M | $-196.3M | $-199.6M | $-178.4M | $-129.0M | $-109.6M | $-118.2M | $-75.8M | $-33.9M | $-15.9M | $-10.3M | $-2.2M | $-179000.00 |
| EBITDA | — | — | — | — | — | — | — | $-188.3M | $-179.1M | $-129.8M | $-110.0M | $-118.4M | $-75.5M | $-33.8M | $-15.8M | $-10.2M | — | — |
| EPS | -17.93 | -17.93 | -14.00 | -18.79 | -2.02 | -1.65 | -2.72 | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -62.1% | -62.1% | -82.2% | -88.7% | -90.5% | -46.8% | -159.0% | -462.9% | -593.0% | -8133.2% | -71903.9% | -47630.4% | -33120.5% | -8772.6% | -2506.3% | -6783.6% | — | — |
| Net Margin | -134.2% | -134.2% | -52.6% | -98.0% | -105.2% | -59.1% | -181.6% | -488.1% | -588.1% | -8036.4% | -71153.9% | -47272.4% | -33090.4% | -8771.8% | -2506.0% | -6783.6% | — | — |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | — | — | — | — | — | -2.12 | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-75.4M | $-75.4M | $-127.6M | $-92.7M | $-149.7M | $-107.3M | $-160.4M | $-191.0M | $-161.5M | $-73.8M | $-84.5M | — | — | — | — | — | — | — |
| Returns | ||||||||||||||||||
| ROE | 66.9% | 66.9% | 41.1% | 105.1% | 992.4% | 155.7% | -388.3% | -401.0% | -97.4% | -99.6% | -67.5% | -59.6% | -36.6% | -21.9% | 57.0% | 81.5% | 94.4% | 100.0% |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 0.6% | 0.6% | -0.5% | -7.0% | -25.1% | 94.1% | 164.3% | 34.8% | 1790.1% | 942.2% | -38.4% | 9.2% | -40.8% | -39.0% | 317.1% | — | — | — |
| EPS Growth | -28.1% | -28.1% | 25.5% | -830.2% | -22.4% | 39.3% | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.